D01.F Belite Bio, Inc

Healthcare Biotechnology Frankfurt Exchange
140.00 EUR
Close of Nov 12, 2026
112.00 169.00
Market cap
EUR 5.64B
P/E
-
P/B
8.09x
ROE
-14.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is D01.F undervalued?

Graham number

The Graham number of Belite Bio, Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Belite Bio, Inc fundamental analysis

No fundamental analysis for Belite Bio, Inc yet.

Belite Bio, Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009,…

Full company profile